Graft assessment for acute rejection after intestinal transplantation: current status and future perspective. (2nd January 2021)

• Record Type: Journal Article
• Authors: Varkey, Jonas
• Is Part Of: Scandinavian journal of gastroenterology. Volume 56:Number 1(2021)
• Page Start: 13
• Page End: 19
• Publication Date: 2021-01-02
• Subjects: Intestinal transplantation -- multivisceral transplantation -- surveillance -- rejection -- biomarkers -- endoscopy -- imaging; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2020.1847318
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Intestinal transplantation has since its inception evolved as a lifesaving treatment option for patients with irreversible intestinal failure who can no longer be sustained on parenteral nutrition. Improvement in short-term survival after transplantation has also justified the expansion of treatment indications. Unfortunately, success is somewhat limited by a plateau observed in long-term survival. The reason for this sub-optimal long-term result experienced in this cohort may in part be attributed to the intestinal graft with the lymphoid content it carries inflicting the host with multiple complications where acute cellular rejection is one of the most common causes for graft loss. Graft monitoring is for this reason of paramount importance and detection of rejection at an early stage essential to enable early instigation of treatment and successful reversal of the pathology. Due to the challenges in diagnosing acute rejection with a noninvasive marker we are still limited to a surveillance protocol using endoscopy and biopsies for the diagnosis of rejection. The purpose of our paper is to review the adequacy of different methods in monitoring the graft for acute rejection using biomarkers, endoscopy and imaging. In conclusion, the evidence base continues to support the use of histology for the diagnosis of acute rejection. The role of biomarkers are still debatable, although markers such as calprotectin might be beneficial in excluding an ongoing process.